Key stats
About NIPPONAMC - NETFPHARMA
Home page
Inception date
Jul 2, 2021
Structure
Open-Ended Fund
Replication method
Physical
Primary advisor
Nippon Life India Asset Management Ltd. (Invt Mgmt)
ISIN
INF204KC1089
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the Nifty Pharma Index before expenses, subject to tracking errs. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
PHARMABEES fund flows account for 29.75 B INR (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, PHARMABEES doesn't pay dividends to its holders.
PHARMABEES shares are issued by Nippon Life Insurance Co. under the brand Nippon. The ETF was launched on Jul 2, 2021, and its management style is Passive.
PHARMABEES expense ratio is 0.19% meaning you'd have to pay 0.19% of your investment to help manage the fund.
PHARMABEES follows the Nifty Pharma Index - INR - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
PHARMABEES price has risen by 0.58% over the last month, and its yearly performance shows a 2.82% increase. See more dynamics on PHARMABEES price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 6.00% over the last month, showed a 12.28% increase in three-month performance and has increased by 38.00% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 6.00% over the last month, showed a 12.28% increase in three-month performance and has increased by 38.00% in a year.
PHARMABEES trades at a premium (0.13%) meaning the ETF is trading at a higher price than the calculated NAV.